Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The SYRE news page on Stock Titan aggregates company press releases, clinical updates, and capital markets announcements so readers can follow how Spyre’s programs and corporate activities evolve over time.
In its public communications, Spyre highlights a pipeline of investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, with programs such as SPY001, SPY002, SPY072, and SPY003. News items frequently cover interim Phase 1 data, such as reports that SPY003 was well tolerated and exhibited an approximately 85-day half-life, and that SPY002 and SPY072 showed pharmacokinetic profiles supporting potential quarterly or twice-yearly maintenance dosing. Updates also describe the design and enrollment status of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Investors and followers of SYRE can also find announcements about stock offerings, use of proceeds, and equity inducement awards granted under the company’s equity plans, as well as participation in scientific congresses and investor conferences. Together, these news items provide insight into Spyre’s clinical development progress, financing activities, and broader corporate strategy as disclosed by the company.
For users tracking SYRE, this page offers a centralized view of Spyre Therapeutics’ official news flow, including trial milestones, interim study findings, and key financing events drawn from press releases and related disclosures.
Spyre Therapeutics (NASDAQ: SYRE) has priced its public offering of 7,275,000 common stock shares at $27.50 per share, expecting to raise $200.0 million in gross proceeds. The clinical-stage biotech company, focused on IBD treatments, has granted underwriters a 30-day option to purchase up to additional 1,091,250 shares. The offering, managed by Jefferies, Goldman Sachs, Evercore Group, and Guggenheim Securities, is expected to close around November 20, 2024.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on inflammatory bowel disease treatment, has announced a proposed public offering of up to $200 million in common stock and pre-funded warrants. The underwriters will have a 30-day option to purchase an additional $30 million of shares. The offering will be managed by Jefferies, Goldman Sachs, Evercore Group, and Guggenheim Securities as joint book-running managers, with LifeSci Capital as lead manager. The offering is subject to market conditions and will be made through a prospectus supplement and accompanying prospectus filed with the SEC.
Spyre Therapeutics (NASDAQ: SYRE) announced positive interim Phase 1 results for SPY001, its novel anti-α4β7 antibody for Inflammatory Bowel Disease treatment. The drug showed a favorable safety profile and exceeded expectations with a >90-day half-life, approximately 4 times longer than vedolizumab. The single lowest dose achieved complete α4β7 receptor saturation through Week 12.
The trial included 56 healthy participants across multiple dosing cohorts, with no serious adverse events reported. Based on these results, Spyre plans to initiate a platform Phase 2 trial in mid-2025, which will evaluate SPY001, SPY002, SPY003, and their combinations for treating ulcerative colitis.
Spyre Therapeutics (NASDAQ: SYRE) announced it will present interim results from its Phase 1 healthy volunteer trial of SPY001, a novel half-life extended anti-α4β7 antibody designed to treat Inflammatory Bowel Disease (IBD). The company will host a conference call and webcast on November 12, 2024, at 8:00am ET to discuss the findings. The webcast will be accessible through Spyre's Investor Relations webpage and will be archived for -time viewing.
Spyre Therapeutics announced its third quarter 2024 financial results and provided corporate updates. The company has $414 million in cash, cash equivalents, and marketable securities as of September 30, 2024, with an expected runway into 2027. Net loss for Q3 2024 was $69 million, compared to $40.1 million in Q3 2023. R&D expenses increased to $44.7 million due to ongoing IBD pipeline development.
Key pipeline updates include:
- SPY001: Interim Phase 1 data expected by year-end 2024.
- SPY002: First-in-human trials to begin in Q4 2024.
- SPY003: Accelerated first-in-human trials to Q1 2025.
New preclinical data for SPY003 showed a three-fold increase in half-life compared to risankizumab. Spyre also plans to investigate combination therapies to maximize efficacy in treating IBD.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, announced the approval of inducement stock options for two non-executive employees. The Compensation Committee granted options to purchase 90,000 shares of common stock under the 2018 Equity Inducement Plan. The options have a 10-year term with an exercise price of $33.98, matching Spyre's closing share price on November 1, 2024. The options vest 25% after one year and the remaining monthly over four years, contingent on continued employment.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in three major healthcare investor conferences this November. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 13), the Stifel 2024 Healthcare Conference (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Live audio webcasts and replays will be accessible through Spyre's investor events website.
Spyre Therapeutics (NASDAQ: SYRE) announced accelerated timelines for SPY003, its novel half-life extended IL-23p19 monoclonal antibody, with first-in-human dosing now expected in Q1 2025. New data presented at UEGW showed SPY003's robust preclinical activity, including comparable potency and >3-fold half-life extension in NHPs relative to risankizumab. Spyre's portfolio now includes extended half-life molecules targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.
Additional preclinical data on SPY003 in combination with SPY001 or SPY002 demonstrated enhanced efficacy and pharmacodynamics. The company expects to share interim data from the accelerated first-in-human trial in H2 2025. Spyre also presented preclinical data on SPY001 (anti-α4β7) and SPY002 (anti-TL1A) at UEGW, supporting potential Q8-12W dosing regimens in IBD.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company focused on Inflammatory Bowel Disease (IBD) treatment, has announced the approval of inducement awards by its independent Compensation Committee. The awards include:
1. Stock options to purchase 400,000 shares of common stock granted to Dr. Sheldon Sloan, the new Chief Medical Officer.
2. Stock options to purchase an aggregate of 129,000 shares of common stock granted to four non-executive employees.
These equity inducement awards were approved on October 1, 2024, under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. The stock options have a 10-year term and an exercise price of $27.46, matching the closing price of Spyre's common stock on October 1, 2024. The vesting schedule includes 25% after one year and 1/48th monthly thereafter, subject to continuous service with Spyre.
Spyre Therapeutics (NASDAQ: SYRE) has appointed Dr. Sheldon Sloan as Chief Medical Officer. Dr. Sloan brings over 25 years of experience in pharmaceutical and biotech companies, with expertise in Inflammation and Immunology. His career includes leadership roles at J&J, Arena Pharmaceuticals, Pfizer, and Abivax.
Dr. Sloan's appointment comes as Spyre prepares to advance its programs into clinical trials over the next several months and initiate Phase 2 studies in 2025. His experience includes leading the Phase 3 development of obefazimod at Abivax and the development of etrasimod at Arena and Pfizer.
Spyre Therapeutics is focused on developing innovative therapies for inflammatory bowel disease (IBD) using antibody engineering, therapeutic combinations, and precision medicine approaches.